Impact of obinutuzumab alone and in combination for follicular lymphoma

Although rituximab-based chemoimmunotherapy prolongs the survival of patients with follicular lymphoma (FL), this disease is considered incurable in most patients. Thus, new therapies are needed not only for those in the relapsed/refractory setting, but also for initial treatment. Obinutuzumab (G, G...

Full description

Saved in:
Bibliographic Details
Published inBlood and lymphatic cancer Vol. 7; pp. 73 - 83
Main Authors Sarraf Yazdy, Maryam, Cheson, Bruce D
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.01.2017
Taylor & Francis Ltd
Dove Medical Press
Subjects
Apoptosis
Biotechnology industry
Cancer
Care and treatment
Cell death
Chemotherapy
Comparative analysis
Cytotoxicity
Development and progression
follicular lymphoma
Immunoglobulins
Immunotherapy
Lymphoma
Lymphomas
Medical research
Medicine, Experimental
Monoclonal antibodies
monoclonal antibody
MRD
Non-Hodgkin's lymphomas
Obinutuzumab
Ofatumumab
Patient outcomes
Review
Studies
Targeted cancer therapy
Tositumomab
Florida
United States
California
United States > US
follicular lymphoma
monoclonal antibody
MRD
obinutuzumab
Online AccessGet full text

Cover

More Information
Summary:Although rituximab-based chemoimmunotherapy prolongs the survival of patients with follicular lymphoma (FL), this disease is considered incurable in most patients. Thus, new therapies are needed not only for those in the relapsed/refractory setting, but also for initial treatment. Obinutuzumab (G, GA101) is a third-generation, fully humanized type II glycoengineered, anti-CD20 monoclonal antibody that results in increased direct cell death and antibody-dependent, cell-mediated cytotoxicity/phagocytosis compared to rituximab. Obinutuzumab has significant antitumor activity when used alone or in combinations in untreated or relapsed refractory FL patients. Studies have demonstrated its ability to prolong progression-free survival and, in some cases, overall survival, and to eliminate minimal residual disease. Several ongoing trials are investigating combinations with chemotherapy, immunomodulators, targeted drugs, and immunotherapy agents. G is generally well tolerated, with associated adverse effects including infusion-related reactions, neutropenia, thrombocytopenia, and reactivation of hepatitis B virus. Future studies with this antibody should focus on identifying predictive markers and developing chemotherapy-free combinations that will improve the outcome of patients with FL.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1179-9889
1179-9889
DOI:10.2147/BLCTT.S114173